María Inmaculada Ibáñez de Cáceres
Investigadora Senior (Contrato Miguel Servet- Tipo 2)
Jefe de Laboratorio
Hospital Universitario La Paz
Javier de Castro Carpeño
Jefe de Sección de Oncología
Profesor Asociado
Hospital Universitario La Paz
Universidad Autónoma de Madrid
Miranda Burdiel Herencia
Investigadora Predoctoral
Hospital Universitario La Paz
Julián Colmenarejo Fernández
Investigador Predoctoral
Hospital Universitario La Paz
Patricia Cruz Castellanos
Facultativo Especialista de Área en Oncología Médica
Hospital Universitario La Paz
María Isabel Esteban Rodríguez
Facultativo Especialista de Área en Anatomía Patológica
Hospital Universitario La Paz
Álvaro García Guede
Investigador Predoctoral
Hospital Universitario La Paz
Julia Jiménez Hernández
Investigadora Predoctoral
Universidad Autónoma de Madrid
Cristina Manguán García
Técnico de Laboratorio
IIB "Alberto Sols"
Olga Pernía Arias
Técnico de Laboratorio (Contrato PTA)
Hospital Universitario La Paz
Rosario Perona Abellón
Profesora de Investigación
IIB "Alberto Sols"
Garcilaso Riesco Eizaguirre
Facultativo Especialista de Área en Endocrinología y Nutrición
Hospital Universitario La Paz
Carlos Rodríguez Antolín
Bioinformático Contratado
Hospital Universitario La Paz
Rocío Rosas Alonso 
Farmacéutica Interna Residente
Hospital Universitario La Paz
Ana Sastre Perona
Investigadora Senior (Contrato Miguel Servet- Tipo I)
Hospital Universitario La Paz
Olga Vera Puente
Investigadora Predoctoral
Hospital Universitario La Paz
Strategic Objective
Our research is focused on two distinct areas:
1- Genetic and epigenetic mechanisms involved in the resistance to chemotherapeutic drugs. Drug resistance is a crucial problem in clinical practice. We have used various strategies to approach this problem, such as identifying new targets involved in drug responses and studying their alterations in human samples. In addition, we have identified epigenetic changes in tumour suppressor genes associated with drug resistance and new gene inducers of chromosome instability associated with drug responses.
We have identified various targets involved in the resistance to platinum-derived compounds in non-small cell lung cancer (NSCLC). One of these targets, MKP1, is a dual-specific phosphatase expressed at high levels in biopsies from early-stage NSCLC and is also associated with tumour progression of this disease. We have worked towards identifying the platinum-resistance epigenetic markers (genes and micro RNAs) for non-invasive cancer diagnosis in NSCLC. By using genomic and expression reactivation techniques, we have found a gene whose promoter is methylated in NSCLC biopsies and predicts resistance to cisplatin with 80% specificity. We also discovered a combination therapy based in sequential treatment of gastric cancer cells with taxol followed by cisplatin, which induces mitotic catastrophe and increases cell death.
2- Strategies to reactivate telomerase activity in human cells with defects in telomerase and premature senescence.
We have identified a genetic suppressor element (GSE) termed 24-2 that, once expressed in human cells, is able to recover telomerase activity and promote survival to cisplatin. This GSE corresponds to an internal fragment of dyskerin, a protein that is part of the telomerase complex.
Expression of this GSE reactivates telomerase activity in cells with X-linked dyskeratosis congenita, a disease that is characterised by bone marrow failure and several other defects associated with a decrease in telomerase activity.
Research Lines
Translational research:
• Identification of predictive genetic and epigenetic biomarkers in the emergence of resistance in cancer and new therapeutic targets in NSCLC and ovarian cancer.
• Identification of novel microRNAs and LncRNAs involved in chemoradiotherapy response in lung and ovarian cancer as well as in rare diseases as biomarkers for clinical use.
• Study of the mechanisms of resistance to chemotherapy in cancer: the role of tumour stem cells in the response to chemotherapy in non-small cell lung cancer.
• Development of new strategies for the treatment of telomerase defective diseases.
Portofolio of services/Prices
Portfolio of services/Prices  (15/06/2021 Version)